Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Non-Current Deffered Revenue (2018 - 2022)

NovaBridge Biosciences (NBP) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $37.7 million as the latest value for Q4 2022.

  • Quarterly Non-Current Deffered Revenue rose 7.5% to $37.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $37.7 million through Dec 2022, up 7.5% year-over-year, with the annual reading at $2.4 million for FY2022, 93.17% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2022 was $37.7 million at NovaBridge Biosciences, up from $35.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $37.7 million in Q4 2022, with the low at $361574.0 in Q4 2018.
  • Average Non-Current Deffered Revenue over 4 years is $18.4 million, with a median of $17.8 million recorded in 2019.
  • The sharpest move saw Non-Current Deffered Revenue soared 53.82% in 2019, then grew 7.5% in 2022.
  • Over 4 years, Non-Current Deffered Revenue stood at $361574.0 in 2018, then surged by 53.82% to $556172.6 in 2019, then surged by 6199.44% to $35.0 million in 2021, then rose by 7.5% to $37.7 million in 2022.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $37.7 million, $35.0 million, and $556172.6 for Q4 2022, Q4 2021, and Q4 2019 respectively.